Document 0273
 DOCN  M94A0273
 TI    Antifungal therapy of yeast infections.
 DT    9412
 AU    Hay RJ; Department of Dermatology, United Medical Schools, Guy's;
       Hospital, London, United Kingdom.
 SO    J Am Acad Dermatol. 1994 Sep;31(3 Pt 2):S6-9. Unique Identifier :
       AIDSLINE MED/94358251
 AB    Candida infections of the skin and mucous membranes are common in both
       healthy and immunocompromised patients. Management with topical azole or
       polyene therapy is generally straightforward except in immunocompromised
       patients with oropharyngeal infections and in Candida onychomycosis.
       Oral candidosis in patients with AIDS generally requires oral therapy
       with fluconazole, itraconazole, or ketoconazole. Continuous suppressive
       therapy carries the risk of the development of clinical tolerance or
       secondary drug resistance. In nail disease, oral antifungal therapy is
       appropriate except in paronychia, for which topical azole antifungals
       appear to be equally effective. In any case it is important to determine
       whether Candida isolated from nail material is a true nail pathogen or
       merely colonizing the nail plate. Distal erosion of the nail plate, the
       presence of underlying host abnormalities such as Raynaud's disease, and
       hyphae in the nail plate are clues that organism is invading the nail
       plate.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Administration,
       Topical  Antifungal Agents/*THERAPEUTIC USE  Candidiasis,
       Cutaneous/*DRUG THERAPY/IMMUNOLOGY/MICROBIOLOGY  Candidiasis,
       Oral/COMPLICATIONS/*DRUG THERAPY/IMMUNOLOGY/  MICROBIOLOGY  Human
       Immunocompromised Host  Onychomycosis/*DRUG
       THERAPY/IMMUNOLOGY/MICROBIOLOGY  Paronychia/*DRUG
       THERAPY/IMMUNOLOGY/MICROBIOLOGY  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).